Skip to main content
. Author manuscript; available in PMC: 2010 Aug 3.
Published in final edited form as: Pain. 2009 Dec 14;148(2):302–308. doi: 10.1016/j.pain.2009.11.015

Fig. 3.

Fig. 3

Intrathecal midazolam (MZL) inhibits neuropathic allodynia in the spinal nerve ligation (SNL) model. (A) Predrug mechanical withdrawal thresholds were measured and MZL was injected intrathecally and mechanical withdrawal thresholds were reassessed at the indicated time points. A significant main effect of MZL was observed (F(5, 246) = 6.31, p < 0.0001). (B) MZL, at the peak effect dose, did not alter mechanical withdrawal thresholds in sham animals. (C) MZL dose-dependently inhibited neuropathic allodynia with an EC50 (D) of 0.97 ± 0.72 ng. *p < 0.05, **p < 0.01 with one-way ANOVA and Dunnett’s post hoc test.